• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
Coregulator control of androgen receptor action by a novel nuclear receptor-binding motif.核心调节剂通过新型核受体结合基序控制雄激素受体的作用。
J Biol Chem. 2014 Mar 28;289(13):8839-51. doi: 10.1074/jbc.M113.534859. Epub 2014 Feb 12.
2
Structural features discriminate androgen receptor N/C terminal and coactivator interactions.结构特征区分雄激素受体 N/C 端和共激活因子的相互作用。
Mol Cell Endocrinol. 2012 Jan 30;348(2):403-10. doi: 10.1016/j.mce.2011.03.026. Epub 2011 Jun 1.
3
Distinct recognition modes of FXXLF and LXXLL motifs by the androgen receptor.雄激素受体对FXXLF和LXXLL基序的不同识别模式。
Mol Endocrinol. 2004 Sep;18(9):2132-50. doi: 10.1210/me.2003-0375. Epub 2004 Jun 3.
4
Allosteric conversation in the androgen receptor ligand-binding domain surfaces.雄激素受体配体结合域表面的变构转换
Mol Endocrinol. 2012 Jul;26(7):1078-90. doi: 10.1210/me.2011-1281. Epub 2012 May 31.
5
Androgen receptor ligand-binding domain interaction and nuclear receptor specificity of FXXLF and LXXLL motifs as determined by L/F swapping.通过亮氨酸/苯丙氨酸交换测定FXXLF和LXXLL基序的雄激素受体配体结合域相互作用及核受体特异性。
Mol Endocrinol. 2006 Aug;20(8):1742-55. doi: 10.1210/me.2005-0348. Epub 2006 Apr 20.
6
Development of Bag-1L as a therapeutic target in androgen receptor-dependent prostate cancer.Bag-1L 在雄激素受体依赖性前列腺癌中的治疗靶点开发。
Elife. 2017 Aug 10;6:e27159. doi: 10.7554/eLife.27159.
7
A conserved surface on the ligand binding domain of nuclear receptors for allosteric control.核受体配体结合域上的变构调控的保守表面。
Mol Cell Endocrinol. 2012 Jan 30;348(2):394-402. doi: 10.1016/j.mce.2011.08.012. Epub 2011 Aug 22.
8
Domain interactions between coregulator ARA(70) and the androgen receptor (AR).共调节因子ARA(70)与雄激素受体(AR)之间的结构域相互作用。
Mol Endocrinol. 2002 Feb;16(2):287-300. doi: 10.1210/mend.16.2.0765.
9
Mechanisms of androgen receptor signalling via steroid receptor coactivator-1 in prostate.雄激素受体通过类固醇受体辅激活因子-1在前列腺中的信号传导机制。
Endocr Relat Cancer. 2004 Mar;11(1):117-30. doi: 10.1677/erc.0.0110117.
10
Modulation of androgen receptor activation function 2 by testosterone and dihydrotestosterone.睾酮和双氢睾酮对雄激素受体激活功能2的调节作用。
J Biol Chem. 2007 Aug 31;282(35):25801-16. doi: 10.1074/jbc.M703268200. Epub 2007 Jun 25.

引用本文的文献

1
Bile acids target an exposed cavity in the glucocorticoid receptor modulating receptor self-assembly, chromatin binding and transcriptional activity.胆汁酸作用于糖皮质激素受体上的一个暴露腔,调节受体的自组装、染色质结合和转录活性。
bioRxiv. 2025 May 16:2025.05.13.653693. doi: 10.1101/2025.05.13.653693.
2
PPAR gamma and PGC-1alpha activators protect against diabetic nephropathy by suppressing the inflammation and NF-kappaB activation.过氧化物酶体增殖物激活受体 γ 和 PGC-1α 激活剂通过抑制炎症和 NF-κB 激活来预防糖尿病肾病。
Nephrology (Carlton). 2024 Dec;29(12):858-872. doi: 10.1111/nep.14381. Epub 2024 Sep 4.
3
Thio-2 Inhibits Key Signaling Pathways Required for the Development and Progression of Castration-resistant Prostate Cancer.硫氧还蛋白-2 抑制剂抑制去势抵抗性前列腺癌发生和发展所需的关键信号通路。
Mol Cancer Ther. 2024 Jun 4;23(6):791-808. doi: 10.1158/1535-7163.MCT-23-0354.
4
Characterization of allosteric modulators that disrupt androgen receptor co-activator protein-protein interactions to alter transactivation-Drug leads for metastatic castration resistant prostate cancer.鉴定破坏雄激素受体共激活蛋白-蛋白相互作用从而改变反式激活的变构调节剂-用于转移性去势抵抗性前列腺癌的药物先导物。
SLAS Discov. 2023 Oct;28(7):325-343. doi: 10.1016/j.slasd.2023.08.001. Epub 2023 Aug 6.
5
Visualization of the protein-protein interactions of hormone receptors in hormone-dependent cancer research.激素依赖性癌症研究中激素受体蛋白-蛋白相互作用的可视化
Endocr Oncol. 2022 Oct 3;2(1):R132-R142. doi: 10.1530/EO-22-0059. eCollection 2022 Jan.
6
The multivalency of the glucocorticoid receptor ligand-binding domain explains its manifold physiological activities.糖皮质激素受体配体结合域的多价性解释了其多样的生理活性。
Nucleic Acids Res. 2022 Dec 9;50(22):13063-13082. doi: 10.1093/nar/gkac1119.
7
Allosteric Antagonism of the Pregnane X Receptor (PXR): Current-State-of-the-Art and Prediction of Novel Allosteric Sites.变构拮抗剂的妊娠相关蛋白 X 受体(PXR):当前的最新研究进展和新变构结合位点的预测。
Cells. 2022 Sep 24;11(19):2974. doi: 10.3390/cells11192974.
8
Structure-Based Study to Overcome Cross-Reactivity of Novel Androgen Receptor Inhibitors.基于结构的研究克服新型雄激素受体抑制剂的交叉反应性。
Cells. 2022 Sep 7;11(18):2785. doi: 10.3390/cells11182785.
9
Epigenetic Coregulation of Androgen Receptor Signaling.雄激素受体信号的表观遗传共调控
Adv Exp Med Biol. 2022;1390:277-293. doi: 10.1007/978-3-031-11836-4_16.
10
Androgen receptor co-regulation in prostate cancer.前列腺癌中的雄激素受体共调节
Asian J Urol. 2020 Jul;7(3):219-232. doi: 10.1016/j.ajur.2019.09.005. Epub 2019 Oct 4.

本文引用的文献

1
Amplitude modulation of androgen signaling by c-MYC.c-MYC 对雄激素信号的幅度调制。
Genes Dev. 2013 Apr 1;27(7):734-48. doi: 10.1101/gad.209569.112. Epub 2013 Mar 25.
2
Beyond the ligand-binding pocket: targeting alternate sites in nuclear receptors.超越配体结合口袋:靶向核受体中的替代结合位点。
Med Res Rev. 2013 Sep;33(5):1081-118. doi: 10.1002/med.21275. Epub 2012 Nov 26.
3
Targeting the binding function 3 (BF3) site of the androgen receptor through virtual screening. 2. development of 2-((2-phenoxyethyl) thio)-1H-benzimidazole derivatives.通过虚拟筛选靶向雄激素受体的结合功能 3(BF3)位点。2. 2-((2-苯氧乙基)硫代)-1H-苯并咪唑衍生物的开发。
J Med Chem. 2013 Feb 14;56(3):1136-48. doi: 10.1021/jm3015712. Epub 2013 Jan 18.
4
EZH2 oncogenic activity in castration-resistant prostate cancer cells is Polycomb-independent.在去势抵抗性前列腺癌细胞中,EZH2 致癌活性是独立于 Polycomb 的。
Science. 2012 Dec 14;338(6113):1465-9. doi: 10.1126/science.1227604.
5
The androgen receptor in health and disease.雄激素受体在健康和疾病中的作用。
Annu Rev Physiol. 2013;75:201-24. doi: 10.1146/annurev-physiol-030212-183656. Epub 2012 Nov 13.
6
A peptidic unconjugated GRP78/BiP ligand modulates the unfolded protein response and induces prostate cancer cell death.一种肽非缀合的 GRP78/BiP 配体调节未折叠蛋白反应并诱导前列腺癌细胞死亡。
PLoS One. 2012;7(10):e45690. doi: 10.1371/journal.pone.0045690. Epub 2012 Oct 1.
7
Allosteric conversation in the androgen receptor ligand-binding domain surfaces.雄激素受体配体结合域表面的变构转换
Mol Endocrinol. 2012 Jul;26(7):1078-90. doi: 10.1210/me.2011-1281. Epub 2012 May 31.
8
Androgen receptor (AR) aberrations in castration-resistant prostate cancer.雄激素受体(AR)异常在去势抵抗性前列腺癌中的作用。
Mol Cell Endocrinol. 2012 Sep 5;360(1-2):38-43. doi: 10.1016/j.mce.2011.12.019. Epub 2012 Jan 8.
9
Regulation of androgen receptor-dependent transcription by coactivator MED1 is mediated through a newly discovered noncanonical binding motif.辅激活因子 MED1 通过新发现的非经典结合基序调节雄激素受体依赖性转录。
J Biol Chem. 2012 Jan 6;287(2):858-70. doi: 10.1074/jbc.M111.304519. Epub 2011 Nov 18.
10
Androgen receptor gene expression in prostate cancer is directly suppressed by the androgen receptor through recruitment of lysine-specific demethylase 1.雄激素受体基因在前列腺癌中的表达被雄激素受体直接抑制,通过募集赖氨酸特异性去甲基化酶 1。
Cancer Cell. 2011 Oct 18;20(4):457-71. doi: 10.1016/j.ccr.2011.09.001.

核心调节剂通过新型核受体结合基序控制雄激素受体的作用。

Coregulator control of androgen receptor action by a novel nuclear receptor-binding motif.

机构信息

From the Institute of Toxicology and Genetics, Karlsruhe Institute of Technology, 76344 Eggenstein-Leopoldshafen, Germany.

出版信息

J Biol Chem. 2014 Mar 28;289(13):8839-51. doi: 10.1074/jbc.M113.534859. Epub 2014 Feb 12.

DOI:10.1074/jbc.M113.534859
PMID:24523409
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC3979403/
Abstract

The androgen receptor (AR) is a ligand-activated transcription factor that is essential for prostate cancer development. It is activated by androgens through its ligand-binding domain (LBD), which consists predominantly of 11 α-helices. Upon ligand binding, the last helix is reorganized to an agonist conformation termed activator function-2 (AF-2) for coactivator binding. Several coactivators bind to the AF-2 pocket through conserved LXXLL or FXXLF sequences to enhance the activity of the receptor. Recently, a small compound-binding surface adjacent to AF-2 has been identified as an allosteric modulator of the AF-2 activity and is termed binding function-3 (BF-3). However, the role of BF-3 in vivo is currently unknown, and little is understood about what proteins can bind to it. Here we demonstrate that a duplicated GARRPR motif at the N terminus of the cochaperone Bag-1L functions through the BF-3 pocket. These findings are supported by the fact that a selective BF-3 inhibitor or mutations within the BF-3 pocket abolish the interaction between the GARRPR motif(s) and the BF-3. Conversely, amino acid exchanges in the two GARRPR motifs of Bag-1L can impair the interaction between Bag-1L and AR without altering the ability of Bag-1L to bind to chromatin. Furthermore, the mutant Bag-1L increases androgen-dependent activation of a subset of AR targets in a genome-wide transcriptome analysis, demonstrating a repressive function of the GARRPR/BF-3 interaction. We have therefore identified GARRPR as a novel BF-3 regulatory sequence important for fine-tuning the activity of the AR.

摘要

雄激素受体(AR)是一种配体激活的转录因子,对于前列腺癌的发展至关重要。它通过其配体结合域(LBD)被雄激素激活,该域主要由 11 个α-螺旋组成。配体结合后,最后一个螺旋被重新组织成激动剂构象,称为激活功能-2(AF-2),以便与共激活剂结合。几个共激活剂通过保守的 LXXLL 或 FXXLF 序列与 AF-2 口袋结合,以增强受体的活性。最近,已经确定了紧邻 AF-2 的一个小分子结合表面作为 AF-2 活性的别构调节剂,称为结合功能-3(BF-3)。然而,BF-3 在体内的作用目前尚不清楚,对于可以与之结合的蛋白质也知之甚少。在这里,我们证明了伴侣蛋白 Bag-1L 的 N 端的重复 GARRPR 基序通过 BF-3 口袋起作用。这一发现得到了以下事实的支持:选择性 BF-3 抑制剂或 BF-3 口袋内的突变会破坏 GARRPR 基序与 BF-3 之间的相互作用。相反,Bag-1L 中的两个 GARRPR 基序中的氨基酸交换可以在不改变 Bag-1L 与染色质结合能力的情况下,破坏 Bag-1L 与 AR 之间的相互作用。此外,Bag-1L 的突变体可以增加雄激素依赖性的 AR 靶基因的激活,在全基因组转录组分析中,证明了 GARRPR/BF-3 相互作用的抑制功能。因此,我们已经确定 GARRPR 是一种新的 BF-3 调节序列,对于精细调节 AR 的活性非常重要。